New Drug Approvals

PENTASA (mesalamine) for oral administration is a controlled-release formulation of mesalamine, an amino-salicylate anti-inflammatory agent for gastrointestinal use. Chemically, mesalamine is 5-amino-2-hydroxybenzoic acid. It has a molecular weight of 153.14.

The structural formula is:

PENTASA (mesalamine) structural formula illustration

25 mar 2013
KYORIN Pharmaceutical has been marketing mesalazine drugs, PENTASA® Tablets
250mg, PENTASA ® Tablets 500mg and PENTASA ® Enema 1g in Japan while continuously engaging in the development for inflammatory bowel diseases (IBD), including Ulcerative colitis and Crohn’s disease.
 NEW
The development of PENTASA® Suppositories 1g has just been successfully completed as a new formulation, which is convenient to patients, that meets therapeutic needs for Ulcerative colitis

View original post

New Drug Approvals

Istradefylline (KW-6002) is a selective antagonist at the A2A receptor. It has been found to be useful in the treatment of Parkinson’s disease.[1] Istradefylline reduces dyskinesia resulting from long-term treatment with classical antiparkinson drugs such as levodopa. Istradefylline is an analog of caffeine.

 

References

Peter A. LeWitt, MD, M. Guttman, James W. Tetrud, MD, Paul J. Tuite, MD, Akihisa Mori, PhD, Philip Chaikin, PharmD, MD, Neil M. Sussman, MD (2008). “Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces off time in Parkinson’s disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)”. Annals of Neurology63 (3): 295–302. doi:10.1002/ana.21315. PMID 18306243.

 

TUE 26 MAR 2013

Kyowa Hakko Kirin, has received approval for NOURIAST tablets 20 mg (istradefylline), a novel antiparkinsonian agent, has been approved for manufacturing and marketing in Japan.
NOURIAST is a selective adenosine A2A receptor antagonist for Parkinson’s disease…

View original post 18 more words

New Drug Approvals

Empagliflozin

26 March 2013

Boehringer Ingelheim and Eli Lilly and Company today announced the European Medicines Agency (EMA) has accepted for review a marketing authorisation application (MAA) for the investigational sodium glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, for the treatment of Type 2 Diabetes (T2D) in adults. The acceptance of the MAA marks the beginning of the review process in the European Union for this potential oral diabetes treatment.

 

A New Drug Application (NDA) for empagliflozin was recently submitted to the Food and Drug Administration (FDA) in the United States for the treatment of Type 2 Diabetes mellitus (T2D) in adults.

Empagliflozin is part of a class of drugs being investigated for the reduction of blood glucose levels in adults with T2D. In clinical trials to date, SGLT2 inhibitors have been shown to reduce blood glucose by removing excess glucose independently of beta cell function and insulin resistance.

* Empagliflozin…

View original post 339 more words

New Drug Approvals

ACAMPROSATE

MAR 26 2013

MHLW JAPAN has approved  Nippon Shinyaku Co’s Regtect (acamprosate) for support maintenance of abstinence in patients with alcohol dependence.

Acamprosate, also known as N-acetyl homotaurine and by the brand name Campral, is a drug used for treating alcohol dependence.

Acamprosate is thought to stabilize the chemical balance in the brain that would otherwise be disrupted by alcoholism, possibly by antagonizing glutamatergic N-methyl-D-aspartate receptors and agonizing gamma-aminobutyric acid (GABA) type A receptors. Reports indicate that acamprosate only works with a combination of attending support groups and abstinence from alcohol.Certain serious side effects include diarrhea, allergic reactions, irregular heartbeats, and low or high blood pressure, while less serious side effects include headaches, insomnia, and impotence. Acamprosate should not be taken by people with kidney problems or allergies to the drug.

Campral is manufactured and marketed in the United States by Forest Laboratories…

View original post 29 more words

Pakistan Education News Blog

Fateh Muhammad Malik has assumed the charge of the Rector, International Islamic University Islamabad (IIUI) from Saturday.

The President of Pakistan, as Chancellor of the International Islamic University, Islamabad appointed him Rector as per clause 12(1) of the IIUI Ordinance 1985. Earlier, Dr. Manzoor Ahmad, the outgoing Rector of the university relinquished the charge of the post of the Rector on February 21 on completion of his tenure.

Prof. Fateh Muhammad Malik is a leading scholar on Iqbaliyat, Urdu language and literature. He was also Chairman, National Language Authority.

Professor Malik is the author of a number of books on Pakistan movement and literacy and cultural themes.

He also served as Professor and Director of the Institute of Pakistan Studies at the Quaid-e-Azam University, Islamabad and as Iqbal Professor at Heidelberg University in Germany. The Nation

View original post

Blog On Pakistan

In this post we will discuss the most fundemental, and arguably the most important, way of determining status of economies from the perspective of ordinary people. We now deviate away from the issue of theoretical economics and focus on practical economics i.e. the real people’s situation. We will do this by using the data showing the number of people living below $1 a day. This is to determine extreme poverty levels.

In 2007/2008, “Human Development Report”, under “03 Human and income poverty: developing countries” section, enlisted the Population living below $1 a day (%) data. This data is also available online on: http://hdrstats.undp.org/indicators/23.html

Population living below $1 a day (%).

Percentage for the concerned countries is:

India Pakistan China Bangladesh
Total Population (in thousands) as of 2004 1,134,403 158,081 1,312,979 153,281
% of population living under $1 a day 34.3 17.0 9.9 41.3
Total number of People living under…

View original post 812 more words

Flower from pakistan

The stats helper monkeys at WordPress.com mulled over how this blog did in 2010, and here’s a high level summary of its overall blog health:

Healthy blog!

The Blog-Health-o-Meter™ reads This blog is doing awesome!.

Crunchy numbers

Featured image

A Boeing 747-400 passenger jet can hold 416 passengers. This blog was viewed about 4,300 times in 2010. That’s about 10 full 747s.

In 2010, there was 1 new post, not terrible for the first year! There were 2 pictures uploaded, taking up a total of 54kb.

The busiest day of the year was October 4th with 45 views. The most popular post that day was Mianwali A city of saraiki speaking .

Where did they come from?

The top referring sites in 2010 were photos.raftaar.in, gulepakistan.co.cc, 74.125.67.100, larki.webs.com, and irfanalikhan.blogspot.com.

Some visitors came searching, mostly for chudai, pixpux.com, pixpux, http://www.pixpux.com, and mast chudai.

Attractions…

View original post 31 more words